Compare Cassava Sciences Inc (FLNA) vs Jones Lang LaSalle Inc (JLL) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

JLL (Jones Lang LaSalle) stock trades at $330.31, up 5.06% on the day, showing strong momentum. The technical picture is bullish, with the price above key resistance levels. Fundamentally, the company has delivered three consecutive earnings beats, with revenue growing to $26.12B in 2025 and net income margin improving to 3.03%. Recent news highlights significant capital markets activity, including a $332M Chicago tower refinancing and a study suggesting AI will drive workforce growth, not cuts.

The outlook is positive, supported by analyst consensus for a 25% upside to a $405.50 price target and a 'Buy' rating from 55% of covering analysts. Key opportunities include continued execution in capital markets and property services, while risks involve exposure to commercial real estate cycles and potential macroeconomic headwinds affecting transaction volumes.